Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | Efficacy and safety results from the ANCHOR trial

Enrique Ocio, MD, PhD, Marquis of Valdecilla University Hospital, Santander, Spain, shares efficacy and safety results from the ANCHOR trial (NCT03481556), which is evaluating the use of melflufen plus dexamethasone and either daratumumab or bortezomib to treat patients with relapsed/refractory (R/R) multiple myeloma. Dr Ocio highlights the overall response rate (ORR), the progression-free survival (PFS), and the adverse events observed in both treatment arms. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.